Medicus Pharma (MDCX) Research & Development (2024 - 2026)

Medicus Pharma's (MDCX) quarterly Research & Development came in at -$996039.0 in Q4 2025, down 111.43% on a QoQ basis from $8.7 million in Q3 2025.

Medicus Pharma (MDCX) Research & Development (2024 - 2026) Analysis & Trends

Medicus Pharma (MDCX) has 2 years of Research & Development data on file, last reported at -$996039.0 in Q4 2025.

Quarterly Research & Development changed N/A year-over-year to -$996039.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11.2 million (up 598.59% YoY) and the FY2025 annual result came in at $7.7 million, changed N/A from the prior year.
Research & Development slipped to -$996039.0 in Q4 2025, from $8.7 million in the prior quarter.
In the past five years, Research & Development ranged from a high of $8.7 million in Q3 2025 to a low of -$996039.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	R&D (Qtr)
1	Johnson & Johnson	652.20 Bn	631.44 Bn	17.26 Bn	3.65 Bn
2	AbbVie	469.51 Bn	462.94 Bn	12.70 Bn	2.34 Bn
3	Merck	376.81 Bn	369.67 Bn	12.21 Bn	9.74 Bn
4	Novartis Ag	303.04 Bn	295.35 Bn	11.24 Bn	2.85 Bn
5	Astrazeneca	257.61 Bn	252.71 Bn	12.86 Bn	4.05 Bn
6	Amgen	237.37 Bn	223.38 Bn	7.24 Bn	1.87 Bn
7	Gilead Sciences	181.73 Bn	178.55 Bn	6.22 Bn	1.76 Bn
8	Pfizer	159.66 Bn	147.96 Bn	10.94 Bn	2.81 Bn
9	Gsk	106.24 Bn	102.07 Bn	8.24 Bn	-4.65 Bn
10	Medicus Pharma	14.88 Mn	-298,205.43	-	4.91 Mn

Download Data